Results 71 to 80 of about 740,964 (300)

SARS-CoV-2 Cross-reactive T cells.

open access: yes, 2021
(A) CD154 upregulation assay of potential cross-reactive epitopes. Top panel: DR0101 SARS- CoV-2 S961-980, middle panel: DR1501 SARS-CoV-2 S1001-1020, and bottom panel: DP0401 SARS-CoV-2 S809-828. SARS-CoV-2 peptide-specific cell lines were generated and
Uma Malhotra (847242)   +7 more
core   +1 more source

T Cell responses to whole SARS Coronavirus in humans [PDF]

open access: yes, 2008
Effective vaccines should confer long-term protection against future outbreaks of severe acute respiratory syndrome (SARS) caused by a novel zoonotic coronavirus (SARS-CoV) with unknown animal reservoirs.
Douek, Daniel C.   +54 more
core   +1 more source

SARS-CoV-2 Uzbekistan MetaData

open access: yes, 2022
Tracking temporal and spatial genomic changes and evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Uzbekistan.
Alisher Abdullaev (12124800)
core   +1 more source

Biophysical approaches for studying viral entry

open access: yesFEBS Letters, EarlyView.
Viruses infect all living organisms and have been responsible for major epidemics and pandemics. Their ongoing evolutionary battle with host defenses creates a constant need for improved tools to study viral behavior. Advancing methods to probe viral attachment, fusion, and genome release deepen our understanding of how infections begin and support the
Inbar Yosibash, Raya Sorkin
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Therapeutic antibodies under development for SARS‐CoV‐2

open access: yesView, 2022
The world is experiencing one of the most difficult moments in history with COVID‐19, which has rapidly developed into a worldwide pandemic with a significant health and economic burden.
Zetong Ma   +7 more
doaj   +1 more source

Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 positivity.

open access: yes, 2022
Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 positivity.
Woottichai Khamduang (147028)   +11 more
core   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

open access: yesFEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Guillain‐Barré syndrome after SARS‐CoV‐2 infection

open access: yesJournal of General and Family Medicine, 2022
We herein report a case of Guillain‐Barré syndrome (GBS) after SARS‐CoV‐2 infection. The patient was a close contact with a SARS‐CoV‐2 patient. Initially, she did not have any symptoms and quarantined at a hotel.
Mikiya Kajita   +5 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy